# JS207 Combination Therapy in Triple-negative Breast Cancer

> **NCT07045311** · PHASE2 · RECRUITING · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 80 (estimated)

## Conditions studied

- Triple-negative Breast Cancer

## Interventions

- **DRUG:** JS207 in combination with 9MW2821
- **DRUG:** JS207 in combination with Albumin paclitaxel

## Key facts

- **NCT ID:** NCT07045311
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-17
- **Primary completion:** 2028-03-22
- **Final completion:** 2029-03-22
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07045311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07045311, "JS207 Combination Therapy in Triple-negative Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07045311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*